B-intervention	0	14	Intraoperative
I-intervention	15	27	radiotherapy
O	28	34	versus
B-control	35	43	external
I-control	44	56	radiotherapy
O	57	60	for
O	61	66	early
O	67	73	breast
O	74	80	cancer
O	81	82	(
O	82	87	ELIOT
O	87	88	)
O	88	89	:
O	90	91	a
O	92	102	randomised
O	103	113	controlled
O	114	125	equivalence
O	126	131	trial
O	131	132	.

O	133	147	Intraoperative
O	148	160	radiotherapy
O	161	165	with
O	166	175	electrons
O	176	182	allows
O	183	186	the
O	187	199	substitution
O	200	202	of
O	203	215	conventional
O	216	229	postoperative
O	230	235	whole
O	236	242	breast
O	243	254	irradiation
O	255	259	with
O	260	263	one
O	264	271	session
O	272	274	of
O	275	287	radiotherapy
O	288	292	with
O	293	296	the
O	297	301	same
O	302	312	equivalent
O	313	317	dose
O	318	324	during
O	325	332	surgery
O	332	333	.

O	334	341	However
O	341	342	,
O	343	346	its
O	347	354	ability
O	355	357	to
O	358	365	control
O	366	369	for
O	370	380	recurrence
O	381	383	of
O	384	389	local
O	390	397	disease
O	398	406	required
O	407	419	confirmation
O	420	422	in
O	423	424	a
O	425	435	randomised
O	436	446	controlled
O	447	452	trial
O	452	453	.

O	454	458	This
O	459	464	study
O	465	468	was
O	469	473	done
O	474	476	at
O	477	480	the
O	481	489	European
O	490	499	Institute
O	500	502	of
O	503	511	Oncology
O	512	513	(
B-location	513	518	Milan
I-location	518	519	,
I-location	520	525	Italy
O	525	526	)
O	526	527	.

O	528	533	Women
O	534	538	aged
B-age	539	541	48
I-age	541	542	-
I-age	542	544	75
I-age	545	550	years
B-eligibility	551	555	with
I-eligibility	556	561	early
I-eligibility	562	568	breast
I-eligibility	569	575	cancer
I-eligibility	575	576	,
I-eligibility	577	578	a
I-eligibility	579	586	maximum
I-eligibility	587	593	tumour
I-eligibility	594	602	diameter
I-eligibility	603	605	of
I-eligibility	606	608	up
I-eligibility	609	611	to
I-eligibility	612	613	2
I-eligibility	613	614	·
I-eligibility	614	615	5
I-eligibility	616	618	cm
I-eligibility	618	619	,
I-eligibility	620	623	and
I-eligibility	624	632	suitable
I-eligibility	633	636	for
I-eligibility	637	643	breast
I-eligibility	643	644	-
I-eligibility	644	654	conserving
I-eligibility	655	662	surgery
O	663	667	were
O	668	676	randomly
O	677	685	assigned
O	686	688	in
O	689	690	a
O	691	692	1
O	692	693	:
O	693	694	1
O	695	700	ratio
O	701	702	(
O	702	707	using
O	708	709	a
O	710	716	random
O	717	725	permuted
O	726	731	block
O	732	738	design
O	738	739	,
O	740	750	stratified
O	751	754	for
O	755	763	clinical
O	764	770	tumour
O	771	775	size
O	776	777	[
O	777	778	<
O	778	779	1
O	779	780	·
O	780	781	0
O	782	784	cm
O	785	787	vs
O	788	789	1
O	789	790	·
O	790	791	0
O	791	792	-
O	792	793	1
O	793	794	·
O	794	795	4
O	796	798	cm
O	799	801	vs
O	802	803	≥
O	803	804	1
O	804	805	·
O	805	806	5
O	807	809	cm
O	809	810	]
O	810	811	)
O	812	814	to
O	815	822	receive
O	823	829	either
O	830	835	whole
O	835	836	-
O	836	842	breast
O	843	851	external
O	852	864	radiotherapy
O	865	867	or
O	868	882	intraoperative
O	883	895	radiotherapy
O	896	900	with
O	901	910	electrons
O	910	911	.

O	912	917	Study
O	918	930	coordinators
O	930	931	,
O	932	942	clinicians
O	942	943	,
O	944	947	and
O	948	956	patients
O	957	961	were
O	962	967	aware
O	968	970	of
O	971	974	the
O	975	985	assignment
O	985	986	.

O	987	995	Patients
O	996	998	in
O	999	1002	the
O	1003	1017	intraoperative
O	1018	1030	radiotherapy
O	1031	1036	group
O	1037	1045	received
O	1046	1049	one
O	1050	1054	dose
O	1055	1057	of
O	1058	1060	21
O	1061	1063	Gy
O	1064	1066	to
O	1067	1070	the
O	1071	1077	tumour
O	1078	1081	bed
O	1082	1088	during
O	1089	1096	surgery
O	1096	1097	.

O	1098	1103	Those
O	1104	1106	in
O	1107	1110	the
O	1111	1119	external
O	1120	1132	radiotherapy
O	1133	1138	group
O	1139	1147	received
O	1148	1150	50
O	1151	1153	Gy
O	1154	1156	in
O	1157	1159	25
O	1160	1169	fractions
O	1170	1172	of
O	1173	1174	2
O	1175	1177	Gy
O	1177	1178	,
O	1179	1187	followed
O	1188	1190	by
O	1191	1192	a
O	1193	1198	boost
O	1199	1201	of
O	1202	1204	10
O	1205	1207	Gy
O	1208	1210	in
O	1211	1215	five
O	1216	1225	fractions
O	1225	1226	.

O	1227	1231	This
O	1232	1235	was
O	1236	1238	an
O	1239	1250	equivalence
O	1251	1256	trial
O	1256	1257	;
O	1258	1261	the
O	1262	1274	prespecified
O	1275	1286	equivalence
O	1287	1293	margin
O	1294	1297	was
O	1298	1303	local
O	1304	1314	recurrence
O	1315	1317	of
O	1318	1319	7
O	1319	1320	·
O	1320	1321	5
O	1321	1322	%
O	1323	1325	in
O	1326	1329	the
O	1330	1344	intraoperative
O	1345	1357	radiotherapy
O	1358	1363	group
O	1363	1364	.

O	1365	1368	The
O	1369	1376	primary
O	1377	1385	endpoint
O	1386	1389	was
B-outcome-Measure	1390	1400	occurrence
I-outcome-Measure	1401	1403	of
I-outcome-Measure	1404	1415	ipsilateral
I-outcome-Measure	1416	1422	breast
I-outcome-Measure	1423	1429	tumour
I-outcome-Measure	1430	1441	recurrences
I-outcome-Measure	1442	1443	(
I-outcome-Measure	1443	1447	IBTR
I-outcome-Measure	1447	1448	)
O	1448	1449	;
B-outcome-Measure	1450	1457	overall
I-outcome-Measure	1458	1466	survival
O	1467	1470	was
O	1471	1472	a
O	1473	1482	secondary
O	1483	1490	outcome
O	1490	1491	.

O	1492	1495	The
O	1496	1500	main
O	1501	1509	analysis
O	1510	1513	was
O	1514	1516	by
O	1517	1526	intention
O	1527	1529	to
O	1530	1535	treat
O	1535	1536	.

O	1537	1541	This
O	1542	1547	trial
O	1548	1550	is
O	1551	1561	registered
O	1562	1566	with
O	1567	1581	ClinicalTrials
O	1581	1582	.
O	1582	1585	gov
O	1585	1586	,
O	1587	1593	number
O	1594	1605	NCT01849133
O	1605	1606	.

B-total-participants	1607	1611	1305
O	1612	1620	patients
O	1621	1625	were
O	1626	1636	randomised
O	1637	1638	(
B-control-participants	1638	1641	654
O	1642	1644	to
O	1645	1653	external
O	1654	1666	radiotherapy
O	1667	1670	and
B-intervention-participants	1671	1674	651
O	1675	1677	to
O	1678	1692	intraoperative
O	1693	1705	radiotherapy
O	1705	1706	)
O	1707	1714	between
O	1715	1718	Nov
O	1719	1721	20
O	1721	1722	,
O	1723	1727	2000
O	1727	1728	,
O	1729	1732	and
O	1733	1736	Dec
O	1737	1739	27
O	1739	1740	,
O	1741	1745	2007
O	1745	1746	.

O	1747	1752	After
O	1753	1754	a
O	1755	1761	medium
O	1762	1768	follow
O	1768	1769	-
O	1769	1771	up
O	1772	1774	of
O	1775	1776	5
O	1776	1777	·
O	1777	1778	8
O	1779	1784	years
O	1785	1786	(
O	1786	1789	IQR
O	1790	1791	4
O	1791	1792	·
O	1792	1793	1
O	1793	1794	-
O	1794	1795	7
O	1795	1796	·
O	1796	1797	7
O	1797	1798	)
O	1798	1799	,
B-iv-bin-abs	1800	1802	35
O	1803	1811	patients
O	1812	1814	in
O	1815	1818	the
O	1819	1833	intraoperative
O	1834	1846	radiotherapy
O	1847	1852	group
O	1853	1856	and
B-cv-bin-abs	1857	1861	four
O	1862	1870	patients
O	1871	1873	in
O	1874	1877	the
O	1878	1886	external
O	1887	1899	radiotherapy
O	1900	1905	group
O	1906	1909	had
O	1910	1913	had
O	1914	1916	an
B-outcome	1917	1921	IBTR
O	1922	1923	(
O	1923	1924	p
O	1924	1925	<
O	1925	1926	0
O	1926	1927	·
O	1927	1931	0001
O	1931	1932	)
O	1932	1933	.

O	1934	1937	The
B-outcome	1938	1939	5
I-outcome	1939	1940	-
I-outcome	1940	1944	year
I-outcome	1945	1950	event
I-outcome	1951	1955	rate
I-outcome	1956	1959	for
I-outcome	1960	1964	IBRT
O	1965	1968	was
B-iv-bin-percent	1969	1970	4
I-iv-bin-percent	1970	1971	·
I-iv-bin-percent	1971	1972	4
I-iv-bin-percent	1972	1973	%
O	1974	1975	(
O	1975	1977	95
O	1977	1978	%
O	1979	1981	CI
O	1982	1983	2
O	1983	1984	·
O	1984	1985	7
O	1985	1986	-
O	1986	1987	6
O	1987	1988	·
O	1988	1989	1
O	1989	1990	)
O	1991	1993	in
O	1994	1997	the
O	1998	2012	intraoperative
O	2013	2025	radiotherapy
O	2026	2031	group
O	2032	2035	and
B-cv-bin-percent	2036	2037	0
I-cv-bin-percent	2037	2038	·
I-cv-bin-percent	2038	2039	4
I-cv-bin-percent	2039	2040	%
O	2041	2042	(
O	2042	2043	0
O	2043	2044	·
O	2044	2045	0
O	2045	2046	-
O	2046	2047	1
O	2047	2048	·
O	2048	2049	0
O	2049	2050	)
O	2051	2053	in
O	2054	2057	the
O	2058	2066	external
O	2067	2079	radiotherapy
O	2080	2085	group
O	2086	2087	(
O	2087	2093	hazard
O	2094	2099	ratio
O	2100	2101	9
O	2101	2102	·
O	2102	2103	3
O	2104	2105	[
O	2105	2107	95
O	2107	2108	%
O	2109	2111	CI
O	2112	2113	3
O	2113	2114	·
O	2114	2115	3
O	2115	2116	-
O	2116	2118	26
O	2118	2119	·
O	2119	2120	3
O	2120	2121	]
O	2121	2122	)
O	2122	2123	.

O	2124	2130	During
O	2131	2134	the
O	2135	2139	same
O	2140	2146	period
O	2146	2147	,
B-iv-bin-abs	2148	2150	34
O	2151	2156	women
O	2157	2166	allocated
O	2167	2169	to
O	2170	2184	intraoperative
O	2185	2197	radiotherapy
O	2198	2201	and
B-cv-bin-abs	2202	2204	31
O	2205	2207	to
O	2208	2216	external
O	2217	2229	radiotherapy
B-outcome	2230	2234	died
O	2235	2236	(
O	2236	2237	p
O	2237	2238	=
O	2238	2239	0
O	2239	2240	·
O	2240	2242	59
O	2242	2243	)
O	2243	2244	.

B-outcome	2245	2246	5
I-outcome	2246	2247	-
I-outcome	2247	2251	year
I-outcome	2252	2259	overall
I-outcome	2260	2268	survival
O	2269	2272	was
B-iv-bin-percent	2273	2275	96
I-iv-bin-percent	2275	2276	·
I-iv-bin-percent	2276	2277	8
I-iv-bin-percent	2277	2278	%
O	2279	2280	(
O	2280	2282	95
O	2282	2283	%
O	2284	2286	CI
O	2287	2289	95
O	2289	2290	·
O	2290	2291	3
O	2291	2292	-
O	2292	2294	98
O	2294	2295	·
O	2295	2296	3
O	2296	2297	)
O	2298	2300	in
O	2301	2304	the
O	2305	2319	intraoperative
O	2320	2332	radiotherapy
O	2333	2338	group
O	2339	2342	and
B-cv-bin-percent	2343	2345	96
I-cv-bin-percent	2345	2346	·
I-cv-bin-percent	2346	2347	9
I-cv-bin-percent	2347	2348	%
O	2349	2350	(
O	2350	2352	95
O	2352	2353	·
O	2353	2354	5
O	2354	2355	-
O	2355	2357	98
O	2357	2358	·
O	2358	2359	3
O	2359	2360	)
O	2361	2363	in
O	2364	2367	the
O	2368	2376	external
O	2377	2389	radiotherapy
O	2390	2395	group
O	2395	2396	.

O	2397	2399	In
O	2400	2408	patients
O	2409	2413	with
O	2414	2418	data
O	2419	2428	available
O	2429	2430	(
O	2430	2431	n
O	2431	2432	=
B-intervention-participants	2432	2435	464
O	2436	2439	for
O	2440	2454	intraoperative
O	2455	2467	radiotherapy
O	2467	2468	;
O	2469	2470	n
O	2470	2471	=
B-control-participants	2471	2474	412
O	2475	2478	for
O	2479	2487	external
O	2488	2500	radiotherapy
O	2500	2501	)
O	2502	2504	we
O	2505	2510	noted
O	2511	2524	significantly
O	2525	2530	fewer
B-outcome	2531	2535	skin
I-outcome	2536	2540	side
I-outcome	2540	2541	-
I-outcome	2541	2548	effects
O	2549	2551	in
O	2552	2557	women
O	2558	2560	in
O	2561	2564	the
O	2565	2579	intraoperative
O	2580	2592	radiotherapy
O	2593	2598	group
O	2599	2603	than
O	2604	2606	in
O	2607	2612	those
O	2613	2615	in
O	2616	2619	the
O	2620	2628	external
O	2629	2641	radiotherapy
O	2642	2647	group
O	2648	2649	(
O	2649	2650	p
O	2650	2651	=
O	2651	2652	0
O	2652	2653	·
O	2653	2657	0002
O	2657	2658	)
O	2658	2659	.

O	2660	2668	Although
O	2669	2672	the
O	2673	2677	rate
O	2678	2680	of
O	2681	2685	IBTR
O	2686	2688	in
O	2689	2692	the
O	2693	2707	intraoperative
O	2708	2720	radiotherapy
O	2721	2726	group
O	2727	2730	was
O	2731	2737	within
O	2738	2741	the
O	2742	2754	prespecified
O	2755	2766	equivalence
O	2767	2773	margin
O	2773	2774	,
O	2775	2778	the
O	2779	2783	rate
O	2784	2787	was
O	2788	2801	significantly
O	2802	2809	greater
O	2810	2814	than
O	2815	2819	with
O	2820	2828	external
O	2829	2841	radiotherapy
O	2841	2842	,
O	2843	2846	and
O	2847	2854	overall
O	2855	2863	survival
O	2864	2867	did
O	2868	2871	not
O	2872	2878	differ
O	2879	2886	between
O	2887	2893	groups
O	2893	2894	.

O	2895	2903	Improved
O	2904	2913	selection
O	2914	2916	of
O	2917	2925	patients
O	2926	2931	could
O	2932	2938	reduce
O	2939	2942	the
O	2943	2947	rate
O	2948	2950	of
O	2951	2955	IBTR
O	2956	2960	with
O	2961	2975	intraoperative
O	2976	2988	radiotherapy
O	2989	2993	with
O	2994	3003	electrons
O	3003	3004	.

O	3005	3012	Italian
O	3013	3024	Association
O	3025	3028	for
O	3029	3035	Cancer
O	3036	3044	Research
O	3044	3045	,
O	3046	3056	Jacqueline
O	3057	3065	Seroussi
O	3066	3074	Memorial
O	3075	3085	Foundation
O	3086	3089	for
O	3090	3096	Cancer
O	3097	3105	Research
O	3105	3106	,
O	3107	3110	and
O	3111	3118	Umberto
O	3119	3127	Veronesi
O	3128	3138	Foundation
O	3138	3139	.
